GenMark Diagnostics (GNMK -3.7%) provides preliminary operational and financial results for FY 2019.
Total revenue for FY 2019 and Q4 is expected to be ~$88M, +24% Y/Y and ~$27M, respectively.
ePlex revenue for FY 2019 and Q4 of ~$60M, +59% Y/Y and ~$19M, respectively.
Gross margin is expected to be between 33% and 34% for Q4 and between 32% and 33% for FY 219.
The Company placed 48 new ePlex analyzers in Q4, for a net increase of 38 to the installed base finishing the year with 527 ePlex analyzers placed worldwide.
ePlex installed base grew 49% Y/Y.
Q4 annuity was ~$148 thousand per analyzer.
The Company expects to issue full 2019 financial results and 2020 guidance in late February.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.